Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GRFS
stocks logo

GRFS

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.91B
+4.82%
--
--
1.91B
+6.34%
--
--
2.07B
+4.61%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Grifols, S.A. (GRFS) for FY2025, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by 41.80%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.56%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.01%
In Past 3 Month
Stock Price
Go Up
up Image
+41.80%
In Past 3 Month
1 Analyst Rating
up Image0
Wall Street analysts forecast GRFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRFS is 10.30 USD with a low forecast of 10.30 USD and a high forecast of 10.30  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
up Image0
Current: 9.940
sliders
Low
10.30
Averages
10.30
High
10.30
up Image0
Current: 9.940
sliders
Low
10.30
Averages
10.30
High
10.30
JPMorgan
James Gordon
Neutral
maintain
2025-06-18
Reason
JPMorgan
James Gordon
Price Target
2025-06-18
maintain
Neutral
Reason
JPMorgan analyst James Gordon raised the firm's price target on Grifols to $10.30 from $7.60 and keeps a Neutral rating on the shares.
JPMorgan
Neutral
maintain
2025-06-18
Reason
JPMorgan
Price Target
2025-06-18
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Grifols to EUR 12 from EUR 9.50 and keeps a Neutral rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Grifols SA (GRFS.O) is 14.15, compared to its 5-year average forward P/E of 17.71. For a more detailed relative valuation and DCF analysis to assess Grifols SA 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
17.71
Current PE
14.15
Overvalued PE
24.18
Undervalued PE
11.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
12.56
Current EV/EBITDA
9.84
Overvalued EV/EBITDA
15.08
Undervalued EV/EBITDA
10.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.43
Current PS
0.96
Overvalued PS
2.14
Undervalued PS
0.73

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 986.97% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

GRFS News & Events

Events Timeline

(ET)
2025-05-30
06:11:45
U.S. court rules to go on with Grifol lawsuit against Gotham City, Reuters says
select
link
2025-05-12 (ET)
2025-05-12
11:45:41
Grifols reaffirms guidance for 2025
select
2025-05-12
11:43:43
Grifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
07-09Benzinga
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday

  • U.S. Stock Market Performance: U.S. stocks rose on Wednesday, with the Dow Jones index increasing by 0.1%, while Verona Pharma's shares surged 20.6% following Merck's announcement of a $10 billion acquisition deal.

  • Notable Stock Gains: Several companies saw significant stock price increases, including Scage Future (up 55.4%), ProKidney Corp (up 47.1%), and Rhythm Pharmaceuticals (up 25.8%) after positive trial results.

Preview
6.5
06-24NASDAQ.COM
Analysts Anticipate KOMP To Hit $60

  • ETF Analysis: The SPDR S&P Kensho New Economies Composite ETF (KOMP) has an implied analyst target price of $60.30, indicating a potential upside of 15.87% from its current trading price of $52.04.

  • Stock Performance Insights: Notable underlying holdings such as Immatics NV, Grifols SA, and Rogers Communications Inc show significant upside potential based on analyst targets, raising questions about the validity of these targets in light of recent market developments.

Preview
4.0
06-17Benzinga
JP Morgan Maintains Neutral on Grifols, Raises Price Target to $10.3

  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and real-time intelligence to help traders succeed in the stock market.

  • Exclusive Community Access: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Grifols SA (GRFS) stock price today?

The current price of GRFS is 9.94 USD — it has decreased -1.09 % in the last trading day.

arrow icon

What is Grifols SA (GRFS)'s business?

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

arrow icon

What is the price predicton of GRFS Stock?

Wall Street analysts forecast GRFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRFS is 10.30 USD with a low forecast of 10.30 USD and a high forecast of 10.30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Grifols SA (GRFS)'s revenue for the last quarter?

Grifols SA revenue for the last quarter amounts to 2.11B USD, increased 10.68 % YoY.

arrow icon

What is Grifols SA (GRFS)'s earnings per share (EPS) for the last quarter?

Grifols SA. EPS for the last quarter amounts to 0.11 USD, increased 22.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Grifols SA (GRFS)'s fundamentals?

The market is revising Downward the revenue expectations for Grifols, S.A. (GRFS) for FY2025, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by 41.80%.
arrow icon

How many employees does Grifols SA (GRFS). have?

Grifols SA (GRFS) has 23833 emplpoyees as of July 19 2025.

arrow icon

What is Grifols SA (GRFS) market cap?

Today GRFS has the market capitalization of 2.57B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free